Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

GeneDx Holdings (WGSWW) Revenue (2020 - 2025)

GeneDx Holdings has reported Revenue over the past 6 years, most recently at $121.0 million for Q4 2025.

  • Quarterly results put Revenue at $121.0 million for Q4 2025, up 26.5% from a year ago — trailing twelve months through Dec 2025 was $427.5 million (up 39.97% YoY), and the annual figure for FY2025 was $427.5 million, up 39.97%.
  • Revenue for Q4 2025 was $121.0 million at GeneDx Holdings, up from $116.7 million in the prior quarter.
  • Over the last five years, Revenue for WGSWW hit a ceiling of $121.0 million in Q4 2025 and a floor of $36.2 million in Q2 2022.
  • Median Revenue over the past 5 years was $61.9 million (2022), compared with a mean of $69.1 million.
  • Biggest five-year swings in Revenue: soared 92.77% in 2022 and later plummeted 35.96% in 2023.
  • GeneDx Holdings' Revenue stood at $57.8 million in 2021, then rose by 6.14% to $61.4 million in 2022, then decreased by 6.41% to $57.4 million in 2023, then surged by 66.57% to $95.6 million in 2024, then increased by 26.5% to $121.0 million in 2025.
  • The last three reported values for Revenue were $121.0 million (Q4 2025), $116.7 million (Q3 2025), and $102.7 million (Q2 2025) per Business Quant data.